Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.